Three Movers to Watch for: CF Industries Holdings, Inc. (CF), MetLife, Inc. (MET), Pfizer Inc. (PFE)

CF Industries Holdings, Inc. (CF) retreated with the stock falling -12.6% or $-3.09 to close at $21.43 on light trading volume of 25.85M compared its three months average trading volume of 4.96M. The Deerfield Illinois 60015 based company operating under the Agricultural Chemicals industry has been trending down for the last 52 weeks, with the shares price now -64.09% down for the period and down by -46.4% so far this year. With price target of $29.5 and a -5.8% rebound from 52-week low, CF Industries Holdings, Inc. has plenty of upside potential, making it a hold with a view buy.

CF Industries Holdings, Inc. manufactures and distributes nitrogen fertilizers and other nitrogen products worldwide. The company operates through Ammonia, Granular Urea, UAN, AN, Other, and Phosphate segments. Its primary nitrogen fertilizer products include ammonia, granular urea, urea ammonium nitrate, and ammonium nitrate. The company also provides diesel exhaust fluid, urea liquor, nitric acid, and aqua ammonia as well as compound fertilizer product, such as nitrogen, phosphorus, and potassium fertilizer. It offers products primarily to cooperatives, independent fertilizer distributors, farmers, and industrial users. CF Industries Holdings, Inc. was founded in 1946 and is based in Deerfield, Illinois.

MetLife, Inc. (MET) dropped $-4.16 to close the day at a new closing price of $39.54, a -9.52% decrease in value from its previous closing price that moved the stock 14.01% above its 52 week low of $35. A total of 25.45M shares exchanged hands during the day compared with its three month average trading volume of 7.3M. The stock, which fluctuated between $38.87 and $41.32 during the day, currently situated -28.32% below its 52 week high. The stock is up by 3.1% in the past one month and down by -7.64% over the past three months. With a one year target estimate of $49.42 and RSI of 36.98, the stock still has upside potential, making it a hold for now.

MetLife, Inc. provides life insurance, annuities, employee benefits, and asset management products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary amp; Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa. The company provides variable, universal, term, and whole life products; individual disability income products; personal lines property and casualty insurance, including private passenger automobile, homeowners, and personal excess liability insurance; and variable and fixed annuities for asset accumulation and distribution needs, as well as mutual funds and other securities products. It also offers group insurance products, such as variable, universal, and term life products; dental, group short- and long-term disability, and accidental death and dismemberment coverages; and voluntary and worksite products consisting of personal lines property and casualty insurance, as well as LTC, prepaid legal plans, and critical illness products. In addition, the company provides annuity and investment products comprising guaranteed interest products and other stable value products, income annuities, and separate account contracts for the investment management of defined benefit and defined contribution plan assets; and structured settlements and products to fund postretirement benefits and company-, bank- or trust-owned life insurance, as well as health insurance, group medical, credit insurance, endowment, retirement, and savings products. It serves individuals and corporations, as well as other institutions and their employees. The company sells its products through sales forces, third-party organizations, independent agents, and property and casualty specialists, as well as through career agency, bancassurance, direct marketing, brokerage, and e-commerce channels. MetLife, Inc. was founded in 1863 and is based in New York, New York.

Pfizer Inc. (PFE) shares were down in last trading by -0.4% to $35.15. It experienced higher than average volume on day. The stock decreased in value by almost -3.35% over the past week and fell -1.17% in the past month. It is currently trading -0.14% below its 50 day moving average and 9.31% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -5.21% decrease in value from its one year high of $37.39. The RSI indicator value of 39.57, lead us to believe that it is a hold for now.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold amp; Sinus, Advil Sinus Congestion Relief amp; Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; and collaborative agreements with Eli Lilly amp; Company, OPKO Health, Inc., BioRap Technologies LTD., and Merck KGaA. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.